That $40 Billion Tylenol Deal Is Both Cheap and Risky

Litigation is supposed to be a deterrent to dealmaking. For Kimberly-Clark Corp., it’s a spur. The diaper maker on Monday agreed to buy Tylenol producer Kenvue Inc. for $40 billion....

By Chris Hughes · Bloomberg

Litigation is supposed to be a deterrent to dealmaking. For Kimberly-Clark Corp., it’s a spur. The diaper maker on Monday agreed to buy Tylenol producer Kenvue Inc. for $40 billion. This mammoth transaction is a gamble — but one with decent odds.